Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATRA and TCP in Relapsed or Refractory AML
NCT02261779Phase 2Unknown
- Sponsor
- Martin Luther University Halle-Wittenberg
- Start
- Sep 2014
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tranylcypromine and tretinoin in acute myeloid leukemia (AML), sponsored by Martin Luther University Halle-Wittenberg. Primary endpoint: Cumulative Response Rate. Status: unknown.
02
Drugs
tranylcyprominetretinoin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02261779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02261779.